# Oral semaglutide: the US changes Canonical: https://europeanpeptideshop.com/blog/oral-ozempic-semaglutide-pill-rybelsus-wegovy/ Explore the catalogue and research library. Ordering and shipping have not opened yet. Research news · 8 November 2026 · 3 min read · By [European Peptide Shop](https://europeanpeptideshop.com/about/) ### On this page Yes: oral Ozempic is a real US prescription product as of this November 5, 2026 check. Ozempic tablets contain semaglutide and were introduced in the US in May. They should be distinguished from Ozempic injections, the older Rybelsus tablet formulation and Wegovy tablets. The shared ingredient does not make the products interchangeable. [1](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/213051Orig1s030ltr.pdf) [2](https://www.novonordisk-us.com/media/press-releases/ozempic-pill-us-availability-type-2-diabetes.html) ## Why do older pages say oral Ozempic is called Rybelsus? FDA's 2026 supplement-approval letter explicitly permits the Rybelsus formulation R2 product name to change to Ozempic tablets. This is why an older article may use Rybelsus where current US material uses Ozempic pill. [1](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/213051Orig1s030ltr.pdf) Novo announced availability from May 4, 2026, and its November quarterly update discusses the May US launch. The name change therefore needs to be read against a date and a market; a statement about an older formulation or another country's branding can otherwise look like a contradiction. [2](https://www.novonordisk-us.com/media/press-releases/ozempic-pill-us-availability-type-2-diabetes.html) [5](https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=919765) ## How do the three oral names compare? The comparison below concerns product identity and US labeling. It is not a substitution chart. The oral Ozempic/Rybelsus label covers adult type 2 diabetes and cardiovascular risk reduction in specified adults with that disease; Wegovy tablets have their own weight-management and cardiovascular indications. [3](https://www.novo-pi.com/rybelsus.pdf) [4](https://www.novo-pi.com/wegovy.pdf) Name | What it refers to | What to keep separate Ozempic tablets | An oral semaglutide product for the labeled type 2 diabetes populations | Ozempic injection has a different dosage form Rybelsus | An earlier oral semaglutide brand/formulation | Older references and remaining labels do not establish identical tablet strengths Wegovy tablets | Oral semaglutide with its own adult weight-management and cardiovascular labeling | Wegovy injection and its additional indications must be checked separately [1](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/213051Orig1s030ltr.pdf) [3](https://www.novo-pi.com/rybelsus.pdf) [4](https://www.novo-pi.com/wegovy.pdf) ## Are Ozempic and Rybelsus tablets equivalent milligram for milligram? No. The combined prescribing information states that Rybelsus and Ozempic tablets are not substitutable on a milligram-for-milligram basis. It also describes an absorption enhancer in the tablet formulation. The label quantity alone cannot be used to calculate an equivalent injection or another tablet product. [3](https://www.novo-pi.com/rybelsus.pdf) For readers comparing articles, this is a useful distinction between chemical identity and pharmaceutical formulation. A table that lists only the word semaglutide and a milligram amount leaves out information needed to identify the finished medicine. ## Does the Wegovy pill have every indication of the injection? The prescribing information separates indications for Wegovy injection and tablets. For example, the MASH liver-disease indication is listed under the injection. A headline about semaglutide or Wegovy should therefore identify the dosage form before extending an approval claim to the pill. [4](https://www.novo-pi.com/wegovy.pdf) Approval of one formulation for one population does not by itself establish an approval for every formulation, age group or condition. Reading the first section of the exact label is more reliable than inferring an indication from a brand name. ## What is the practical way to check a new oral-semaglutide headline? Record four details: the market, the exact brand and dosage form, the labeled population, and the source date. Then separate an existing approval from a new trial, a proposed indication or a commercial launch. Each event answers a different question. These medicines also carry warnings and contraindications; a pill format does not remove them. The official labels, rather than this naming guide, are the reference for clinical prescribing and product changes. [3](https://www.novo-pi.com/rybelsus.pdf) [4](https://www.novo-pi.com/wegovy.pdf) ## Scope for European readers This is a dated account of the research or policy described in the linked sources. The stated jurisdiction, study product and population matter. A US or UK announcement does not establish authorisation or availability across Europe. Nothing in this report establishes results for an EPS catalogue material. Read the [research-use statement](https://europeanpeptideshop.com/research-use/) for the storefront's scope. ## Laboratory research only Materials listed on this site are supplied for in-vitro laboratory research and are not for use in or on humans or animals. They are not medicines. This article summarises published work and gives no dosing, administration, treatment or in-vivo guidance. Findings from a study apply to the material and conditions of that study, and they say nothing about any product listed here. ## References - [FDA: approval of the Rybelsus R2 name change to Ozempic tablets](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/213051Orig1s030ltr.pdf) - [Novo Nordisk US: Ozempic pill availability, May 1, 2026](https://www.novonordisk-us.com/media/press-releases/ozempic-pill-us-availability-type-2-diabetes.html) - [Novo Nordisk: November 4, 2026 quarterly announcement](https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=919765) - [Rybelsus and Ozempic tablets: US prescribing information](https://www.novo-pi.com/rybelsus.pdf) - [Wegovy injection and tablets: US prescribing information](https://www.novo-pi.com/wegovy.pdf) ## More articles Research news · 3 min read ## [Oral VK2735 and the SUNRISE trials](https://europeanpeptideshop.com/blog/oral-vk2735-sunrise-phase-3/) Understand oral VK2735's SUNRISE-1 and SUNRISE-2 Phase 3 studies, their populations, endpoints and how they differ from injectable VK2735 trials. 8 November 2026 Comparisons · 4 min read ## [Retatrutide, tirzepatide and semaglutide](https://europeanpeptideshop.com/blog/retatrutide-vs-tirzepatide-vs-semaglutide/) Compare retatrutide, tirzepatide and semaglutide by receptor targets, clinical evidence and product status, with clear explanations of trial comparisons. 8 November 2026 Comparisons · 3 min read ## [Tirzepatide versus semaglutide](https://europeanpeptideshop.com/blog/tirzepatide-vs-semaglutide/) The two molecules differ in sequence origin, receptor coverage and lipid chain, and the published head-to-head trials compare the medicines, not research. 8 November 2026